Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesVilazodone, a novel dual-acting serotonergic antidepressant for managing major depression
Expert Opinion on Investigational Drugs, 10/02/09
Khan A – Vilazodone offers a dual mechanism of action, good general tolerability with the potential for less impairment of sexual function than selective serotonin reuptake inhibitors and the possibility of personalized treatment for MDD.
Related Articles
Glutamate-based antidepressants: 20 years on
Trends in Pharmacological Sciences, 10/29/09
Relevance Score: 66%
The Role of Sodium Channels in the Mechanism of Action of Antidepressants and Mood Stabilizers
Current Drug Targets, 10/30/09
Relevance Score: 64%
Direct agonist activity of tricyclic antidepressants at distinct opioid receptor subtypes
Journal of Pharmacology and Experimental Therapeutics, 10/26/09
Relevance Score: 64%
Early induction of CREB activation and CREB-regulating signalling by antidepressants
International Journal of Neuropsychopharmacology, 10/21/09
Relevance Score: 64%
Use of Antidepressants for Management of Hot Flashes
Pharmacotherapy, 10/27/09
Relevance Score: 63%
Today in Neuro/Psych pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Lundbeck initiates clinical phase II trials with Lu AE58054 as augmentation treatment in Alzheimer's disease
Lundbeck, 11/29/09
Use of Antidepressants in the Treatment of Chronic Pain
Annals, Academy of Medicine, Singapore, 11/29/09
Mitoxantrone treatment in multiple sclerosis induces TH2-type cytokines
Acta Neurologica Scandinavica, 11/27/09
Sponsor
Article Search
Sponsor